Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/390d824b-1646-4982-88f9-bfe659de5d61/

WHWK

Whitehawk Therapeutics, Inc.
Chart
3.85 USD
Latest Week 2026-07-31
Snapshot 2026-07-26 · 1.0w · Fresh
0.28
OS Score
40.0%
Value
38.0%
Quality
40.0%
Momentum
4/9
F-Score
0.390
QV
Strategy Eligibility
1 of 23 passing
OS Composite
Trending Value
Quality × Value
🏛
Cornerstone Value
🌿
Cornerstone Growth
💎
Deep Value
VC2 Cheapest
📐
EBITDA/EV
Veiled Value
Piotroski Bargains
🔬
Quality Compounders
📈
Consistent Earners
🌱
GARP
🔄
Shareholder Yield
💰
High Yield
🚀
Momentum Leaders
Market Leaders
Tiny Titans
🔍
Small Cap Value
🛡
Low Volatility
🏷
Sector Cheapest
🧠
Capital Allocators
Risk-Adj Momentum
RAM 2.05
V
Value Analysis
Cheapness relative to fundamentals
40.0%ile
P/B
1.6×
FCF Yield
-0.725
SH Yield
-0.545
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
61.00000000
/100 — 1=cheapest
VC2 (Trending Value)
61.00000000
/100
VC3 (Buyback)
61.00000000
/100
Negative FCF yield (-72.5%) — the business is currently cash-consumptive.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
38.0%ile
ROE
-0.997
ROA
-0.910
GPA
0.000
D/E
0.10
Current
11.36
F-Score
4/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Stability
3.285
lower=better
Accruals
-0.063
lower=better
5yr Consist
No
Conservative balance sheet with D/E of 0.10.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
40.0%ile
6M Return
37.4%
12M Return
90.3%
12-1 Mom
113.3%
Risk-Adj
2.05
Vol 252d
55.2%
Vol 60d
132.2%
↑ Expanding
Max DD 12M
-21.4%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of 113% is very strong — a clear uptrend. Risk-adjusted momentum of 2.05 is excellent — strong returns relative to volatility. Near-term vol (132%) is expanding vs long-term (55%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.28
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
Sector Context
Healthcare · 500 peers
Sector Value %ile
10.0%
Sector Quality %ile
8.0%
P/B z-score
-0.24
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
INVA Innoviva Inc 97.0% 94.0% 94.0% 67.0%
Factor Interactions
Volatility Expanding
60-day vol (132%) significantly exceeds 252-day (55%). Near-term risk is elevated.
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
F
28.5% avg (3 factors)
Quality
C
47.1% avg (6 factors)
Momentum
A
90.2% avg (4 factors)
Risk
F
24.6% avg (1 factors)
Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.280—2
Value %ile0.400—0
Quality %ile0.380—0
Momentum %ile0.400—0
F-Score4.000—8
Confidence0.639—0
Volatility0.552—8
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
Price / Book
1.58
FCF Yield
-72.5%
Shareholder Yield
Div + net buyback / mktcap
-54.5%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
-99.7%
Return on Assets
-91.0%
Gross Profit / Assets
Novy-Marx GPA
-0.0%
Debt / Equity
0.10
Current Ratio
11.36
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.063
MomentumPrice trend strength over different horizons
6M Return
37.4%
12M Return
90.3%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
113.3%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
2.05
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Earnings Stability (CV)
Lower = more stable
3.285
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
4
Buyback Yield
-54.5%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
61
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
61
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
61
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity